Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Clin. Cancer Res 2021 Dec 29;[EPub Ahead of Print], YS Lu, SA Im, M Colleoni, F Franke, A Bardia, F Cardoso, N Harbeck, S Hurvitz, L Chow, J Sohn, KS Lee, S Campos-Gomez, R Villanueva Vazquez, KH Jung, KG Babu, P Wheatley-Price, M De Laurentiis, YH Im, S Kuemmel, N El-Saghir, R O'Regan, C Gasch, N Solovieff, C Wang, Y Wang, A Chakravartty, Y Ji, D TripathyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.